These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3446165)

  • 21. Aminoglycoside forecasting in neutropenic patients with cancer.
    Kosirog JL; Rospond RM; Destache C; Hall P
    Clin Pharmacokinet; 1993 Jan; 24(1):79-87. PubMed ID: 8448975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serial pharmacokinetic dosing of aminoglycosides: a community hospital experience.
    Hoffa DE
    Ther Drug Monit; 1989 Sep; 11(5):574-9. PubMed ID: 2815234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nlmixr2 Versus NONMEM: An Evaluation of Maximum A Posteriori Bayesian Estimates Following External Evaluation of Gentamicin and Tobramycin Population Pharmacokinetic Models.
    Duong A; Marsot A
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):739-747. PubMed ID: 38465725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods.
    Franson TR; Quebbeman EJ; Whipple J; Thomson R; Bubrick J; Rosenberger SL; Ausman RK
    Crit Care Med; 1988 Sep; 16(9):840-3. PubMed ID: 3402229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematically individualizing tobramycin dosage regimens.
    Cipolle RJ; Seifert RD; Zaske DE; Strate RG
    J Clin Pharmacol; 1980 Oct; 20(10):570-80. PubMed ID: 7440765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination.
    Bookstaver PB; Johnson JW; McCoy TP; Stewart D; Williamson JC
    Ann Pharmacother; 2008 Dec; 42(12):1758-65. PubMed ID: 19047358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy.
    Prins JM; Weverling GJ; de Blok K; van Ketel RJ; Speelman P
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2494-9. PubMed ID: 8913452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients.
    Lee C; Walker SAN; Walker SE; Seto W; Simor A; Jeschke M
    Burns; 2017 Dec; 43(8):1766-1774. PubMed ID: 28647460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance.
    Lim AK; Mathanasenarajah G; Larmour I
    Intern Med J; 2015 Mar; 45(3):319-29. PubMed ID: 25581282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of a dosage individualization table for extended-interval gentamicin in neonates.
    Dersch-Mills D; Akierman A; Alshaikh B; Yusuf K
    Ann Pharmacother; 2012; 46(7-8):935-42. PubMed ID: 22739714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aminoglycoside pharmacokinetics in African-Americans with normal renal function.
    Oparaoji EC; Siram S; Elemihe U; Mezghebe HM; Cho T; Bashiri M; Piedrahita K; Pipalla RS
    J Clin Pharm Ther; 1998 Jun; 23(3):191-7. PubMed ID: 9831970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study].
    Reimann IR; Meier-Hellmann A; Pfeifer R; Traut T; Schilling A; Stein G; Reinhart K; Hoffmann A
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):288-95. PubMed ID: 10372218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of gentamicin peak and trough concentrations from six extended-interval dosing protocols for neonates.
    Murphy JE
    Am J Health Syst Pharm; 2005 Apr; 62(8):823-7. PubMed ID: 15821275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates.
    Hoff DS; Wilcox RA; Tollefson LM; Lipnik PG; Commers AR; Liu M
    Pharmacotherapy; 2009 Nov; 29(11):1297-305. PubMed ID: 19857147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of higher dose extended interval aminoglycosides in a neonatal intensive care unit.
    Ohler KH; Menke JA; Fuller L
    Am J Perinatol; 2000; 17(6):285-90. PubMed ID: 11144309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized-pharmacokinetic dosing regimens.
    Pancorbo S; Compty C; Heissler J
    Biopharm Drug Dispos; 1982; 3(1):83-8. PubMed ID: 7082782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients.
    Townsend PL; Fink MP; Stein KL; Murphy SG
    Crit Care Med; 1989 Feb; 17(2):154-7. PubMed ID: 2914447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of a dosage individualization table for extended interval gentamicin in neonates beyond the first week of life.
    Dersch-Mills D; Akierman A; Alshaikh B; Sundaram A; Yusuf K
    J Matern Fetal Neonatal Med; 2016; 29(9):1451-6. PubMed ID: 26043646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.